Immunotherapy has transformed cancer treatment paradigms by harnessing the body's immune system to combat malignancies. However, hypersensitivity reactions (HSRs) associated with these agents pose significant challenges in oncology nursing. This review provides an in-depth analysis of HSRs to cancer immunotherapy regarding incidence, clinical manifestations, and management, and discusses the crucial role of nurses in early detection, patient education, and supportive care. A narrative review approach was used. Literature was systematically searched in PubMed, Embase, CINAHL, and Scopus databases for studies published up to 2025, focusing on immunotherapy-related HSRs, nursing management strategies, and evidence-based care guidelines. Relevant clinical guidelines and position statements from the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN) were also reviewed. Oncology nurses must be aware of HSRs and enhance their nursing practices in order to mitigate risks and optimize patient outcomes.
Citation: Ioanna Tsatsou. Managing hypersensitivity reactions in cancer immunotherapy: A comprehensive nursing perspective[J]. AIMS Allergy and Immunology, 2025, 9(4): 223-237. doi: 10.3934/Allergy.2025017
Immunotherapy has transformed cancer treatment paradigms by harnessing the body's immune system to combat malignancies. However, hypersensitivity reactions (HSRs) associated with these agents pose significant challenges in oncology nursing. This review provides an in-depth analysis of HSRs to cancer immunotherapy regarding incidence, clinical manifestations, and management, and discusses the crucial role of nurses in early detection, patient education, and supportive care. A narrative review approach was used. Literature was systematically searched in PubMed, Embase, CINAHL, and Scopus databases for studies published up to 2025, focusing on immunotherapy-related HSRs, nursing management strategies, and evidence-based care guidelines. Relevant clinical guidelines and position statements from the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN) were also reviewed. Oncology nurses must be aware of HSRs and enhance their nursing practices in order to mitigate risks and optimize patient outcomes.
| [1] | Sonar PV, Singh AK, Mandadi S, et al. (2025) Expanding horizons of cancer immunotherapy: Hopes and hurdles. Front Oncol 15: 1511560. https://doi.org/10.3389/fonc.2025.1511560 |
| [2] | Schneider BJ, Naidoo J, Santomasso BD, et al. (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39: 4073-4126. https://doi.org/10.1200/JCO.21.01440 |
| [3] | Komatsu H, Hara A, Koyama F, et al. (2025) Enhancing high reliability in oncology care: The critical role of nurses—A systematic review and thematic analysis. Healthcare 13: 283. https://doi.org/10.3390/healthcare13030283 |
| [4] | Rasmussen TH, Mortz CG, Pfeiffer P, et al. (2025) Prevalence and management of immediate drug hypersensitivity observed during antineoplastic drug therapy. Acta Oncol 64: 574-584. https://doi.org/10.2340/1651-226X.2025.43098 |
| [5] | Cummings GG, Lee SD, Tate KC (2018) The evolution of oncology nursing: Leading the path to change. Can Oncol Nurs J 28: 314-317. |
| [6] | Martins F, Sofiya L, Sykiotis GP, et al. (2019) Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol 16: 563-580. https://doi.org/10.1038/s41571-019-0218-0 |
| [7] | Yin Q, Wu L, Han L, et al. (2023) Immune-related adverse events of immune checkpoint inhibitors: A review. Front Immunol 14: 1167975. https://doi.org/10.3389/fimmu.2023.1167975 |
| [8] | Paul F, Cartron G (2019) Infusion-related reactions to rituximab: Frequency, mechanisms and predictors. Expert Rev Clin Immunol 15: 383-389. https://doi.org/10.1080/1744666X.2019.1562905 |
| [9] | Picard M, Galvão VR (2017) Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract 5: 600-609. https://doi.org/10.1016/j.jaip.2016.12.001 |
| [10] | Baldo BA (2014) Side effects of cytokines approved for therapy. Drug Saf 37: 921-943. https://doi.org/10.1007/s40264-014-0226-z |
| [11] | Waldmann TA (2018) Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol 10: a028472. https://doi.org/10.1101/cshperspect.a028472 |
| [12] | Zhao J, Chen Y, Ding ZY, et al. (2019) Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment. Front Pharmacol 10: 1184. https://doi.org/10.3389/fphar.2019.01184 |
| [13] | Dribin TE, Schnadower D, Spergel JM, et al. (2021) Severity grading system for acute allergic reactions: A multidisciplinary Delphi study. J Allergy Clin Immunol 148: 173-181. https://doi.org/10.1016/j.jaci.2021.01.003 |
| [14] | Puzanov I, Diab A, Abdallah K, et al. (2017) Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer Toxicity Management Working Group. J Immunother Cancer 5: 95. https://doi.org/10.1186/s40425-017-0300-z |
| [15] | Barroso A, Estevinho F, Hespanhol V, et al. (2024) Management of infusion-related reactions in cancer therapy: Strategies and challenges. ESMO Open 9: 102922. https://doi.org/10.1016/j.esmoop.2024.102922 |
| [16] | Galateanu B, Puşcaşu AI, Tircol SA, et al. (2023) Allergy in cancer care: antineoplastic therapy-induced hypersensitivity reactions. Int J Mol Sci 24: 3886. https://doi.org/10.3390/ijms24043886 |
| [17] | Rieger PT, Yarbro CH (2003) Role of the oncology nurse. Holland-Frei Cancer Medicine . Hamilton (ON): BC Decker. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13570/ |
| [18] | Ernstmeyer K, Christman E (2021) Nursing Skills. Eau Claire (WI): Chippewa Valley Technical College. Available from: https://www.ncbi.nlm.nih.gov/books/NBK593197/ |
| [19] | Clemmons A, Gandhi A, Clarke A, et al. (2021) Premedications for cancer therapies: A primer for the hematology/oncology provider. J Adv Pract Oncol 12: 810-832. https://doi.org/10.6004/jadpro.2021.12.8.4 |
| [20] | Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9: e002435. https://doi.org/10.1136/jitc-2021-002435 |
| [21] | Teixeira-Poit SM, Sawicki K, O'Kelley W, et al. (2023) Efficacy of a patient education session for cancer patients receiving immunotherapy. Semin Oncol Nurs 39: 151445. https://doi.org/10.1016/j.soncn.2023.151445 |
| [22] | McLendon K, Sternard BT (2025) Anaphylaxis. StatPearls . Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482124/ |
| [23] | Wiley K, LeFebvre KB, Wall L, et al. (2017) Immunotherapy administration: Oncology nursing society recommendations. Clin J Oncol Nurs 21: 5-7. https://doi.org/10.1188/17.CJON.S2.5-7 |
| [24] | NCCNNCCN Guidelines® Insights–Management of Immunotherapy-Related Toxicities, Version 2.2024 (2024). Available from: https://education.nccn.org/node/94879 |
| [25] | Barber FD (2019) Adverse events of oncologic immunotherapy and their management. Asia-Pac J Oncol Nurs 6: 212-226. https://doi.org/10.4103/apjon.apjon_6_19 |
| [26] | Peterson DNP (2023) Management of immunotherapy infusion reactions. Clin J Oncol Nurs 27: 123-128. |
| [27] | Gliklich RE, Dreyer NA, Leavy MB (2014) Registries for Evaluating Patient Outcomes: A User's Guide. Rockville (MD): Agency for Healthcare Research and Quality (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK208615/ |
| [28] | Madrigal-Burgaleta R, Banerji A, Vazquez-Revuelta P, et al. (2025) New approaches to chemotherapeutic drug allergy: From drug challenge to desensitization. J Allergy Clin Immunol Pract 13: 955-966. https://doi.org/10.1016/j.jaip.2025.02.042 |
| [29] | Lasa-Blandon M, Stasi K, Hehir A, et al. (2019) Patient education issues and strategies associated with immunotherapy. Semin Oncol Nurs 35: 150933. https://doi.org/10.1016/j.soncn.2019.08.012 |
| [30] | Friedman AJ, Cosby R, Boyko S, et al. (2011) Effective teaching strategies and methods of delivery for patient education: A systematic review and practice guideline recommendations. J Cancer Educ 26: 12-21. https://doi.org/10.1007/s13187-010-0183-x |
| [31] | Chiang AC, Ellis P, Zon R (2017) Perspectives on the use of clinical pathways in oncology care. Am Soc Clin Oncol Educ Book 37: 155-159. https://doi.org/10.1200/EDBK_175533 |
| [32] | Upton J (2017) Creating guidelines for managing the side-effects of immunotherapy. Nurs Times 114: 24-25. |
| [33] | Wood LS (2019) Immune-related adverse events from immunotherapy: Incorporating care step pathways to improve management across tumor types. J Adv Pract Oncol 10: 47-62. https://doi.org/10.6004/jadpro.2019.10.2.13 |
| [34] | Greer M (2022) Nurses have immediate access to necessary medications and supplies with hypersensitivity reaction kits. ONS Voice . |
| [35] | Freitas MSHS, Fuly PSC (2020) Nursing care in the management of hypersensitivity reaction in patients undergoing antineoplastic therapy: Review for clinical practice. Res Soc Dev 9: e442974263. https://doi.org/10.33448/rsd-v9i7.4263 |
| [36] | Tan S, Day D, Nicholls SJ, et al. (2022) Immune checkpoint inhibitor therapy in oncology: Current uses and future directions. JACC CardioOncol 4: 579-597. https://doi.org/10.1016/j.jaccao.2022.09.004 |
| [37] | Al Wachami N, Chahboune M, Youlyouz-Marfak I, et al. (2024) Improving the quality of care and patient safety in oncology: The contribution of simulation-based training—a scoping review. Int J Nurs Sci 11: 187-196. https://doi.org/10.1016/j.ijnss.2024.03.005 |
| [38] | Lancaster E, Wick E (2021) Standardized care pathways as a means to improve patient safety. Surg Clin North Am 101: 49-56. https://doi.org/10.1016/j.suc.2020.08.011 |
| [39] | Mihaila RI, Gheorghe AS, Zob DL, et al. (2024) The importance of predictive biomarkers and their correlation with the response to immunotherapy in solid tumors: impact on clinical practice. Biomedicines 12: 2146. https://doi.org/10.3390/biomedicines12092146 |
| [40] | Justiz-Vaillant A, Pandit BR, Unakal C, et al. (2025) A comprehensive review about the use of monoclonal antibodies in cancer therapy. Antibodies 14: 35. https://doi.org/10.3390/antib14020035 |
| [41] | Snively A (2025) Master hypersensitivity reactions with these strategies for prevention and management. ONS Voice . |
| [42] | Arimon-Pagès E, Torres-Puig-Gros J, Fernández-Ortega P, et al. (2019) Emotional impact and compassion fatigue in oncology nurses: Results of a multicentre study. Eur J Oncol Nurs 43: 101666. https://doi.org/10.1016/j.ejon.2019.09.007 |
| [43] | Naqvi MR, Abbas S, Abbas M, et al. (2025) Immune boosters and immunotherapy in allergic diseases and in cancer management. Arch Razi Inst 80: 271-274. |
| [44] | Selamoglu Z, Naeem MY (2025) Biological activities of caffeic acid phenethyl ester: Comparative analysis of natural products and synthetic derivatives. Arch Razi Inst . |
| [45] | Ebadi AG, Selamoglu Z, Issa HY, et al. (2025) Next-generation vaccines and antiviral platforms: Molecular advancements in the struggle against emerging zoonotic and viral diseases. Arch Razi Inst 80: 555-568. |
| [46] | Selamoglu Z, Naeem MY, Selamoglu B, et al. (2025) The use and importance of artificial intelligence in vaccine research, development and production. Arch Razi Inst . |
| [47] | Naeem MY, Alp Arici EC, Abbas S, et al. (2025) Current research on the relationships between oxytocin and the immune system: An updated study. Arch Razi Inst . |
Figures(1) / Tables(3)
Ioanna Tsatsou. Managing hypersensitivity reactions in cancer immunotherapy: A comprehensive nursing perspective[J]. AIMS Allergy and Immunology, 2025, 9(4): 223-237. doi: 10.3934/Allergy.2025017
DownLoad: